Global Anticoagulants Market Size, Share, Growth Analysis, By Drug class(Vitamin K Antagonists (VKAs) and Direct Oral Anticoagulants (DOACs)), By Distribution channel(Hospital Pharmacies, Retail Pharmacies) - Industry Forecast 2024-2031

Report ID: SQMIG35B2093 | Region: Global | Published Date: March, 2024
Pages: 219 | Tables: 61 | Figures: 75

Global Anticoagulants Market News

In June 2023, Boehringer Ingelheim announced a partnership with Twist Bioscience Corporation to discover and develop novel anticoagulant therapies using synthetic biology and next-generation sequencing technologies.

In May 2023, Janssen Pharmaceuticals launched Xarelto® (rivaroxaban) in India for the prevention and treatment of venous thromboembolism, stroke, and atrial fibrillation.

In April 2023, Merck & Co., Inc. announced an investment of $1 billion to expand its manufacturing facility in the United States, focusing on the production of cardiovascular and anticoagulant therapies.

In February 2023, Novartis completed the acquisition of The Medicines Company, expanding its portfolio of cardiovascular medicines, including anticoagulants.

In January 2023, Bristol Myers Squibb announced a collaboration with Schrödinger, Inc. to utilize computational design for the discovery of novel anticoagulant therapies.

Global Anticoagulants Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

The Global Anticoagulants Market size size was valued at USD 28.50 Billion in 2022 and is poised to grow from USD 31.44 Billion in 2023 to USD 68.87 Billion by 2031, at a CAGR of 10.30% during the forecast period (2024-2031).

The global anticoagulants market is characterized by a diverse range of pharmaceutical companies and research institutions striving to develop innovative anticoagulant therapies. These players focus on research and development activities to introduce novel treatment options with improved efficacy and safety profiles. Collaborations and partnerships are also common strategies to enhance product portfolios and expand market reach. Additionally, regulatory approvals and clinical trials play a crucial role in shaping the competitive dynamics of the market, as they determine the commercial success of new anticoagulant drugs. 'Pfizer Inc. (US)', 'Bayer AG (Germany)', 'Bristol Myers Squibb Company (US)', 'Johnson & Johnson (US)', 'Boehringer Ingelheim International GmbH (Germany)', 'Sanofi S.A. (France)', 'Daiichi Sankyo Company, Limited (Japan)', 'Novartis International AG (Switzerland)', 'Eli Lilly and Company (US)', 'AstraZeneca PLC (UK)', 'Merck & Co., Inc. (US)', 'GlaxoSmithKline PLC (UK)', 'Abbott Laboratories (US)', 'Aspen Pharmacare Holdings Limited (South Africa)', 'Otsuka Holdings Co., Ltd. (Japan)', 'Mylan N.V. (US)', 'Takeda Pharmaceutical Company Limited (Japan)', 'Leo Pharma A/S (Denmark)', 'Portola Pharmaceuticals, Inc. (US)', 'CSL Limited (Australia)'

One key driver of the global anticoagulants market is the increasing prevalence of cardiovascular diseases, including ischemic heart disease (IHD), worldwide. With millions of deaths each year attributed to cardiovascular diseases, there is a growing need for effective treatments to prevent heart attacks and strokes. This rising disease burden has resulted in a higher demand for anticoagulant medications, driving the growth of the market. Additionally, the adoption of novel oral anticoagulants (NOACs) has further fueled the market expansion, offering improved safety and convenience compared to traditional anticoagulants.

One key trend in the global anticoagulants market is the increasing adoption of direct oral anticoagulants (DOACs) over traditional anticoagulant therapies such as warfarin. DOACs offer advantages such as predictable dosing, fewer drug interactions, and reduced need for frequent monitoring compared to warfarin. The shift towards DOACs is driven by the convenience and improved safety profiles they offer, leading to better patient adherence. Additionally, ongoing research and development efforts are focused on expanding the range of indications for DOACs, further driving their popularity in the market.

North America holds a significant share in the global anticoagulants market. The region's dominance can be attributed to several factors, including a high prevalence of cardiovascular diseases, a well-established healthcare infrastructure, and the presence of key market players. The United States, in particular, plays a crucial role in driving the growth of the anticoagulants market in North America, owing to its large population and advanced healthcare system.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Global Anticoagulants Market Size, Share, Growth Analysis, By Drug class(Vitamin K Antagonists (VKAs) and Direct Oral Anticoagulants (DOACs)), By Distribution channel(Hospital Pharmacies, Retail Pharmacies) - Industry Forecast 2024-2031

Global Anticoagulants Market News

Global Anticoagulants Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Anticoagulants Market?

Who are the key vendors in the Global Anticoagulants Market?

What is the key driver of Global Anticoagulants Market?

What is the key market trend for Global Anticoagulants Market?

Which region accounted for the largest share in Global Anticoagulants Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300